{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:59:40Z","timestamp":1792058380671,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00520-025-09211-4","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T06:27:34Z","timestamp":1739341654000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["MASCC antiemetic consensus recommendations: resource-limited settings"],"prefix":"10.1007","volume":"33","author":[{"given":"Snezana M.","family":"Bosnjak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Zilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatraman","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Ostwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gralla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"9211_CR1","doi-asserted-by":"publisher","first-page":"102195","DOI":"10.1016\/j.esmoop.2023.102195","volume":"9","author":"J Herrstedt","year":"2023","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, Aapro M, Dennis K, Hesketh PJ, Navari RM, Schwartzberg L, Affronti ML, Garcia-Del-Barrio MA, Chan A, Celio L, Chow R, Fleury M, Gralla RJ, Giusti R, Jahn F, Iihara H, Maranzano E, Radhakrishnan V, Saito M, Sayegh P, Bosnjak S, Zhang L, Lee J, Ostwal V, Smit T, Zilic A, Jordan K, Scott\u00e9 F, participants of the MASCC\/ESMO Consensus Conference 2022 (2023) MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open 9:102195. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102195","journal-title":"ESMO Open"},{"key":"9211_CR2","doi-asserted-by":"publisher","first-page":"101631","DOI":"10.1016\/j.esmoop.2023.101631","volume":"8","author":"T Cufer","year":"2023","unstructured":"Cufer T, Kosty MP (2023) ESMO\/ASCO recommendations for a global curriculum in medical oncology edition 2023. ESMO Open 8:101631. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101631","journal-title":"ESMO Open"},{"key":"9211_CR3","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1023\/A:1008471812316","volume":"9","author":"Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC)","year":"1998","unstructured":"Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Ann Oncol 9:811\u2013819","journal-title":"Ann Oncol"},{"key":"9211_CR4","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1200\/JCO.1999.17.9.2971","volume":"17","author":"RJ Gralla","year":"1999","unstructured":"Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hasketh PJ, Chinnery LW et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17:2971\u20132994. https:\/\/doi.org\/10.1200\/JCO.1999.17.9.2971","journal-title":"J Clin Oncol"},{"key":"9211_CR5","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38:2782\u20132797. https:\/\/doi.org\/10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"9211_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2022.01.028","volume":"166","author":"M Aapro","year":"2022","unstructured":"Aapro M, Caprariu Z, Chilingirov P, Chr\u00e1pav\u00e1 M, Curca RO, Gales L, Grigorescu AC, Karlinova B, Kellnerova R, Malej\u010dikova M, Marinca M, Petru E, P\u0142u\u017canski A, Pokorn\u00e1 P, Pribulova Z, Rubach M, Steger GG, Tesa\u0159ov\u00e1 P, Valekova L, Yordanov N, Walaszkowska-Czyz A (2022) Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: results of the nausea\/emesis registry in oncology (NERO). Eur J Cancer 166:126\u2013133. https:\/\/doi.org\/10.1016\/j.ejca.2022.01.028","journal-title":"Eur J Cancer"},{"key":"9211_CR7","doi-asserted-by":"crossref","unstructured":"Collin-Lefebvre T, Iyer JK (2020) How do we make sure everybody in the world has access to medicines?. Front Young Minds 8:35. https:\/\/kids.frontiersin.org\/articles\/10.3389\/frym.2020.00035. Accessed Aug 10, 2024","DOI":"10.3389\/frym.2020.00035"},{"key":"9211_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/JGO.2015.002477","volume":"16","author":"B Gyawali","year":"2016","unstructured":"Gyawali B, Poudyal BS, Iddawela M (2016) Cheaper options in the prevention of chemotherapy-induced nausea and vomiting. J Glob Oncol 16:145\u2013153. https:\/\/doi.org\/10.1200\/JGO.2015.002477","journal-title":"J Glob Oncol"},{"key":"9211_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1200\/OP.21.00466","volume":"18","author":"A Gupta","year":"2022","unstructured":"Gupta A, Nshuti L, Grewal US, Sedhom R, Check DK, Parsons HM, Blaes AH, Virnig BA, Lustberg MB, Subbiah IM, Nipp RD, Dy SM, Dusetzina SB (2022) Financial burden of drugs prescribed for cancer-associated symptoms. JCO Oncol Pract 18:140\u2013147. https:\/\/doi.org\/10.1200\/OP.21.00466 Available online on September 24.2021, at (https:\/\/ascopubs.org\/doi\/pdf\/10.1200\/OP.21.00466)","journal-title":"JCO Oncol Pract"},{"key":"9211_CR10","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00520-018-4400-1","volume":"27","author":"S Chanthawong","year":"2019","unstructured":"Chanthawong S, Lim YH, Subongkot S, Chan A, Andalusia R, Ahmad Bustamam RS, Chaiyakunapruk N (2019) Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study. Support Care Cancer 27:1109\u20131119. https:\/\/doi.org\/10.1007\/s00520-018-4400-1","journal-title":"Support Care Cancer"},{"key":"9211_CR11","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3389\/fonc.2020.00400","volume":"10","author":"AK Vaid","year":"2020","unstructured":"Vaid AK, Gupta S, Doval DC, Agarwal S, Nag S, Patil P, Goswami C, Ostwal V, Bhagat S, Patil S, Barkate H (2020) Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective. Front Oncol 10:400. https:\/\/doi.org\/10.3389\/fonc.2020.00400","journal-title":"Front Oncol"},{"key":"9211_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","volume":"47","author":"A Molassiotis","year":"2014","unstructured":"Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N, Burke TA, Gu A, Roila F (2014) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from European prospective observational study. J Pain Symptom Manag 47:839-848.e4. https:\/\/doi.org\/10.1016\/j.jpainsymman.2013.06.012","journal-title":"J Pain Symptom Manag"},{"key":"9211_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00520-023-08221-4","volume":"32","author":"J Herrstedt","year":"2024","unstructured":"Herrstedt J, Celio L, Hesketh PJ, Zhang L, Navari R, Chan A, Saito M, Chow R, Aapro M (2024) 2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. Support Care Cancer 32:47. https:\/\/doi.org\/10.1007\/s00520-023-08221-4","journal-title":"Support Care Cancer"},{"key":"9211_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00520-023-08222-3","volume":"32","author":"F Scott\u00e9","year":"2024","unstructured":"Scott\u00e9 F, Schwartzberg L, Iihara H, Aapro M, Gralla R, Hesketh PJ, Jordan K, Chow R, Herrstedt J (2024) 2023 updated MASCC\/ESMO Consensus recommendations: prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Support Care Cancer 32:45. https:\/\/doi.org\/10.1007\/s00520-023-08222-3","journal-title":"Support Care Cancer"},{"key":"9211_CR15","doi-asserted-by":"publisher","first-page":"102512","DOI":"10.1016\/j.ctrv.2023.102512","volume":"115","author":"M Filetti","year":"2023","unstructured":"Filetti M, Lombardi P, Giusti R, Falcone R, Scotte F, Giannarelli D, Carcagn\u00ec A, Altamura V, Scambia G, Daniele G (2023) Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis. Cancer Treat Rev 115:102512. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102512","journal-title":"Cancer Treat Rev"},{"issue":"Suppl.2","key":"9211_CR16","doi-asserted-by":"publisher","first-page":"S76.eP004","DOI":"10.1007\/s00520-018-4193-2","volume":"26","author":"JN Galeas","year":"2018","unstructured":"Galeas JN, Gralla RJ, Azimi-Nekoo E, Walsh D (2018) Guidelines for the prevention of chemotherapy induced nausea and vomiting (CINV) do not address economic variation, affordability in different populations, and drug availability. MASCC\/ISOO annual meeting. Supp Care Cancer 26(Suppl.2):S76.eP004. https:\/\/doi.org\/10.1007\/s00520-018-4193-2","journal-title":"Supp Care Cancer"},{"key":"9211_CR17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy induced nausea and vomiting: a randomized phase III trial. Study J Supp Oncol 9:188\u2013195. https:\/\/doi.org\/10.1016\/j.suponc.2011.05.002","journal-title":"Study J Supp Oncol"},{"key":"9211_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.12788\/jcso.0245","volume":"14","author":"RM Navari","year":"2016","unstructured":"Navari RM, Nagy CK, Le-Rademacher J, Loprinzi CL (2016) Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J Community Support Oncol 14:141\u2013147. https:\/\/doi.org\/10.12788\/jcso.0245","journal-title":"J Community Support Oncol"},{"key":"9211_CR19","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/oncolo\/oyad140","volume":"28","author":"RM Navari","year":"2023","unstructured":"Navari RM, Le-Rademacher J, Smieliauskas F, Ruddy KJ, James Saphner T, Liu H, Harlos E, Onitilo AA, Giridhar K, Paul Singh P, Reddy PS, Chow S, Kruter F, Raptis G, Loprinzi CL (2023) Olanzapine with or without fosaprepitant for preventing chemotherapy induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: a phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602). Oncologist 28:722\u2013729. https:\/\/doi.org\/10.1093\/oncolo\/oyad140","journal-title":"Oncologist"},{"key":"9211_CR20","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1007\/s00520-020-05380-6","volume":"28","author":"S Ithimakin","year":"2020","unstructured":"Ithimakin S, Theeratrakul P, Laocharoenkiat A, Nimmannit A, Akewanlop C, Soparattanapaisarn N, Techawattanawanna S, Korphaisarn K, Danchaivijitr P (2020) Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. Support Care Cancer 28:5335\u20135342. https:\/\/doi.org\/10.1007\/s00520-020-05380-6","journal-title":"Support Care Cancer"},{"key":"9211_CR21","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.31557\/APJCP.2022.23.6.2137","volume":"23","author":"S Sukauichai","year":"2022","unstructured":"Sukauichai S, Ketkaew C, Othaganont N, Pichaya P, Promsuwan P (2022) Efficacy of olanzapine 5 mg versus 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting in patients receiving high emetic risk chemotherapy without neurokinin-1 receptor antagonist. Asian Pac J Cancer Prev 23:2137\u20132143. https:\/\/doi.org\/10.31557\/APJCP.2022.23.6.2137","journal-title":"Asian Pac J Cancer Prev"},{"key":"9211_CR22","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.2217\/fon-2020-0834","volume":"17","author":"S Mukhopadhyay","year":"2021","unstructured":"Mukhopadhyay S, Dutta P, Banerjee S, Bhattacharya B, Biswas S, Navari RM (2021) Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study. Future Oncol 17:2041\u20132056. https:\/\/doi.org\/10.2217\/fon-2020-0834","journal-title":"Future Oncol"},{"key":"9211_CR23","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/annonc\/mdl137","volume":"17","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441\u20131449. https:\/\/doi.org\/10.1093\/annonc\/mdl137","journal-title":"Ann Oncol"},{"key":"9211_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","volume":"10","author":"M Saito","year":"2009","unstructured":"Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115\u2013124. https:\/\/doi.org\/10.1016\/S1470-2045(08)70313-9","journal-title":"Lancet Oncol"},{"key":"9211_CR25","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1007\/s00520-016-3203-5","volume":"24","author":"K Kubota","year":"2016","unstructured":"Kubota K, Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T (2016) Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens. Support Care Cancer 24:4025\u20134033. https:\/\/doi.org\/10.1007\/s00520-016-3203-5","journal-title":"Support Care Cancer"},{"key":"9211_CR26","doi-asserted-by":"publisher","first-page":"e1066","DOI":"10.1002\/onco.13772","volume":"26","author":"C Sakai","year":"2021","unstructured":"Sakai C, Shimokawa M, Iihara H, Fujita Y, Ikemura S, Hirose C, Kotake M, Funaguchi N, Gomyo T, Imai H, Hakamata J, Kaito D, Minato K, Arai T, Kawazoe H, Suzuki A, Ohno Y, Okura H (2021) Low-dose olanzapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic malignancies: a prospective multicenter phase II trial. Oncologist 26:e1066\u2013e1072. https:\/\/doi.org\/10.1002\/onco.13772","journal-title":"Oncologist"},{"key":"9211_CR27","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00520-007-0248-5","volume":"15","author":"RM Navari","year":"2007","unstructured":"Navari RM, Einhorn LH, Loehrer PJ Sr, Passik SD, Vinson J, McClean J, Chowhan N, Hanna NH, Johnson CS (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 15:1285. https:\/\/doi.org\/10.1007\/s00520-007-0248-5","journal-title":"Support Care Cancer"},{"key":"9211_CR28","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1200\/OP.21.00500","volume":"14","author":"H Iihara","year":"2023","unstructured":"Iihara H, Shimokawa M, Bando H, Niwa Y, Mizuno Y, Kawaguchi Y, Kitahora M, Murakami A, Kawai M, Ishida K, Takeuchi M, Ishihara K, Iyoda T, Nakada T, Ogiso A, Kojima Y, Kumagai F, Sawa A, Mori R, Higuchi K, Furuta T, Kamei Y, Tsuchiya M, Terasaki A, Yamamoto S, Kitazawa M, Okazaki M, Suzuki A, Futamura M (2023) Doublet or triplet antiemetic prophylaxis for nausea and vomiting induced by trastuzumab deruxtecan: an open-label, randomized, and multicenter exploratory phase 2 study. J Cancer 14:2644\u20132654. https:\/\/doi.org\/10.1200\/OP.21.00500","journal-title":"J Cancer"},{"key":"9211_CR29","doi-asserted-by":"publisher","first-page":"100282","DOI":"10.1016\/j.jcpo.2021.100282","volume":"28","author":"M Lawler","year":"2021","unstructured":"Lawler M, Oliver K, Gijssels S, Aapro M, Abolina A, Albreht T, Erdem S, Geissler J, Jassem J, Karjalainen S, La Vecchia C, Lievens Y, Meunier F, Morrisey M, Neredi P, Oberst S, Poortmans P, Price R, Sullivan R, Velikova G, Vrdoljak E, Wilking N, Yared W, Selbey P (2021) The European code of cancer practice. J Cancer Policy 28:100282. https:\/\/doi.org\/10.1016\/j.jcpo.2021.100282","journal-title":"J Cancer Policy"},{"key":"9211_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/annonc\/mdx757","volume":"29","author":"K Jordan","year":"2018","unstructured":"Jordan K, Aapro M, Kaasa S, Ripamonti CI, Scott\u00e9 F, Strasser F, Young A, Bruera E, Herrstedt J, Keefe D, Laird B, Walsh D, Douillard JY, Cervantes A (2018) European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Ann Oncol 29:36\u201343. https:\/\/doi.org\/10.1093\/annonc\/mdx757","journal-title":"Ann Oncol"},{"key":"9211_CR31","unstructured":"World Health Organization Model List of Essential Medicines \u2013 23rd List (2023) The selection and use of essential medicines 2023: executive summary of the report of the 24th WHO Expert Committee on the Selection and Use of Essential Medicines, 24 \u2013 28 April 2023. Geneva: World Health Organization; 2023 (WHO\/MHP\/HPS\/EML\/2023.01) Accessed online at https:\/\/iris.who.int\/bitstream\/handle\/10665\/371291\/WHO-MHP-HPS-EML-2023.01-eng.pdf?sequence=1. Accessed 29 Dec 2024"},{"key":"9211_CR32","unstructured":"NCCN harmonized guidelines for Sub-Saharan Africa. Antiemesis, version 2.2023-December 4 (2023). Accessed at https:\/\/www.nccn.org\/global\/what-we-do\/harmonized-guidelines. Accessed 29 Dec 2024"},{"key":"9211_CR33","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.22.01997","volume":"41","author":"L Sandhya","year":"2023","unstructured":"Sandhya L, Devi Sreenivasan N, Goenka L, Dubashi B, Kayal S, Solaiappan M, Govindarajalou R, Kt H, Ganesan P (2023) Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer. J Clin Oncol 41:2617\u20132627. https:\/\/doi.org\/10.1200\/JCO.22.01997","journal-title":"J Clin Oncol"},{"key":"9211_CR34","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/SPC.0000000000000206","volume":"10","author":"S Bosnjak","year":"2016","unstructured":"Bosnjak S, Dimitrijevic J, Djordjevic F (2016) Cancer and chemotherapy induced-nausea and vomiting: a focus on olanzapine. Curr Opin Support Palliat Care 10:180\u2013188. https:\/\/doi.org\/10.1097\/SPC.0000000000000206","journal-title":"Curr Opin Support Palliat Care"},{"issue":"16 suppl","key":"9211_CR35","doi-asserted-by":"publisher","first-page":"e24078","DOI":"10.1200\/JCO.2022.40.16_suppl.e24078","volume":"40","author":"O Mohammed","year":"2022","unstructured":"Mohammed O, Thota N (2022) Efficacy, safety and cost effectiveness of reduced-dose olanzapine versus aprepitantasa part of triple-antiemetic therapy in the prevention of chemotherapy induced nausea and vomiting. ASCO annual meeting I. J Clin Oncol 40(16 suppl):e24078. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e24078 Available on June 2.2022. at (https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2022.40.16_suppl.e24078)","journal-title":"J Clin Oncol"},{"key":"9211_CR36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00520-016-3313-0","volume":"25","author":"J Herrstedt","year":"2017","unstructured":"Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, Chan A, Aapro MS (2017) 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer 25:277\u2013288. https:\/\/doi.org\/10.1007\/s00520-016-3313-0","journal-title":"Support Care Cancer"},{"key":"9211_CR37","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1186\/s12885-021-08572-3","volume":"21","author":"S Yamamoto","year":"2021","unstructured":"Yamamoto S, Iihara H, Uozumi R, Kawazoe H, Tanaka K, Fujita Y, Abe M, Imai H, Karayama M, Hayasaki Y, Hirose C, Suda T, Nakamura K, Suzuki A, Ohno Y, Morishige KI, Inui N (2021) Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials. BMC Cancer 21:832. https:\/\/doi.org\/10.1186\/s12885-021-08572-3","journal-title":"BMC Cancer"},{"key":"9211_CR38","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12885-022-09392-9","volume":"22","author":"S Yamamoto","year":"2022","unstructured":"Yamamoto S, Iihara H, Uozumi R, Kawazoe H, Tanaka K, Fujita Y, Abe M, Imai H, Karayama M, Hayasaki Y, Hirose C, Suda T, Nakamura K, Suzuki A, Ohno Y, Morishige KI, Inui N (2022) Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis. BMC Cancer 22:310. https:\/\/doi.org\/10.1186\/s12885-022-09392-9","journal-title":"BMC Cancer"},{"key":"9211_CR39","doi-asserted-by":"publisher","unstructured":"Inui N, Suzuki T, Tanaka K, Karayama M, Inoue Y, Mori K, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Matsuura S, Nishimoto K, Matsui T, Asada K, Hashimoto D, Fujii M, Niwa M, Uehara M, Matsuda H, Koda K, Ikeda M, Inami N, Tamiya Y, Kato M, Nakano H, Mino Y, Enomoto N, Suda T (2024) Olanzapine plus triple antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting: a randomized, double-blind, placebo-controlled phase III trial. J Clin Oncol 2400278. https:\/\/doi.org\/10.1200\/JCO.24.00278 (Accessed online at https:\/\/ascopubs.org\/doi\/10.1200\/JCO.24.00278)","DOI":"10.1200\/JCO.24.00278"},{"key":"9211_CR40","doi-asserted-by":"publisher","first-page":"e2426076","DOI":"10.1001\/jamanetworkopen.2024.26076","volume":"7","author":"V Ostwal","year":"2024","unstructured":"Ostwal V, Ramaswamy A, Mandavkar S, Bhargava P, Naughane D, Sunn SF, Srinivas S, Kapoor A, Mishra BK, Gupta A, Sansar B, Pal V, Pandey A, Bonda A, Siripurapu I, Muddu VK, Kannan S, Chaugule D, Patil R, Parulekar M, Dhanawat A, Trikha M, Ghosh J, Noronha V, Menon N, Patil V, Prabhash K, Olver I (2024) Olanzapine as antiemetic prophylaxis in moderately emetogenic chemotherapy: a phase 3 randomized clinical trial. JAMA Netw Open 7:e2426076. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.26076","journal-title":"JAMA Netw Open"},{"issue":"24","key":"9211_CR41","doi-asserted-by":"publisher","first-page":"03995","DOI":"10.1016\/j.annonc.2024.09.001","volume":"S0923\u20137534","author":"H Sakai","year":"2024","unstructured":"Sakai H, Tsurutani J, Ozaki Y, Ishiguro H, Nozawa K, Yamanaka T, Aogi K, Matsumoto K, Iwasa T, Tokiwa M, Tsuneizumi M, Miyoshi Y, Kitagawa C, Yamamoto M, Takano Y, Imamura CK, Chiba Y, Takiguchi D, Ezumi T, Takano T (2024) A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B). Ann Oncol S0923\u20137534(24):03995\u20134. https:\/\/doi.org\/10.1016\/j.annonc.2024.09.001","journal-title":"Ann Oncol"},{"key":"9211_CR42","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/OP.21.00727","volume":"18","author":"F Giap","year":"2022","unstructured":"Giap F, Chino F (2022) What oncologists must account for: the financial burden of cancer-associated symptom relief. JCO Oncol Pract 18:106\u2013108. https:\/\/doi.org\/10.1200\/OP.21.00727","journal-title":"JCO Oncol Pract"},{"key":"9211_CR43","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1200\/JCO.22.02198","volume":"4","author":"JA Paice","year":"2023","unstructured":"Paice JA, Bohlke K, Barton D, Craig DS, El-Jawahri A, Hershman DL, Kong LR, Kurita GP, LeBlanc TW, Mercadante S, Novick KLM, Sedhom R, Seigel C, Stimmel J, Bruera E (2023) Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. J Clin Oncol 4:914\u2013930. https:\/\/doi.org\/10.1200\/JCO.22.02198","journal-title":"J Clin Oncol"},{"key":"9211_CR44","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1200\/OP.21.00500","volume":"18","author":"W Haque","year":"2022","unstructured":"Haque W, Sedhom R, Chino F, Royce TJ, Gupta A (2022) Payer-imposed quantity limits for antiemetics: everybody hurts. JCO Oncol Pract 18:313\u2013317. https:\/\/doi.org\/10.1200\/OP.21.00500","journal-title":"JCO Oncol Pract"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09211-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09211-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09211-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T01:28:55Z","timestamp":1742002135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09211-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["9211"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09211-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SB has received personal fees as an invited speaker from ADOC, Amicus, BMS, Hemofarm, La Roche Posay and PharmaSwiss; she reports non-financial interests as President of the Serbian Association for Supportive Care in Cancer, member of the Central Eastern Europe Regional Council of ASCO, as well as a member of the Palliative and Supportive Care Faculty of ESMO and ESCO. AZ has received fees as invited speaker from Sandoz and travel expenses support from PharmaSwiss and Salveo. VO has received travel\/accommodation expenses as an invited speaker from AstraZeneca, Merck and as an advisory board member for Lupin and Natco; he reports institutional financial interests as an advisory board member for AstraZeneca, Natco, Panaceo, Reddy's Lab and Zydus Cadila; institutional drug support from Alkem, Eisai, Intas and Micro Labs; institutional funding from Reddy's Lab and Zydus Cadila; he reports non-financial interests for leadership roles in Every Nation Mumbai India and the Indian Association of Supportive Care in Cancer. MA has received personal fees as an invited speaker from Amgen and ViforPharma; personal fees as an advisory board member for Astellas; personal financial interests as a member of the Board of Directors of the International Society of Geriatric Oncology (SIOG) and Union for International Cancer Control (UICC); grants to Sharing Progress in Cancer Care (SPCC) from AstraZeneca, BMS, Daiichi Sankyo, ExactSciences, Fresenius Kabi, Helsinn, Mundipharma, Novartis, Pfizer and Roche; institutional financial interests as a member of the Board of Directors of All. Can International and SPCC; he reports non-financial interests for advisory roles to various companies subject to confidentiality agreements, membership of the American Society of Clinical Oncology (ASCO), MASCC and Sociedade Brasileira de Oncologia Cl\u00ednica (SBOC), leadership roles at SIOG and SPCC, and a member of the Scientific Advisory Board of the European School of Oncology (ESO). HI received personal fees from Astellas, AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Nippon Boehringer Ingelheim, Nippon Kayaku, Ohara, Sawai, Taiho and Yakult, and consulting fees for their institution from Taiho and Eisai, as well as personal fees from Daiichi Sankyo, Astellas, and Taiho. All other authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"181"}}